Predictors of sentinel lymph node metastasis in postoperatively upgraded invasive breast carcinoma patients

Chi Chang Yu, Yun Chung Cheung, Chuen Hsueh, Shin Cheh Chen*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

5 Scopus citations


Sentinel lymph node (SLN) biopsy (SLNB) usually need not be simultaneously performed with breast-conserving surgery (BCS) for patients diagnosed with ductal carcinoma in situ (DCIS) by preoperative core needle biopsy (CNB), but must be performed once there is invasive carcinoma (IC) found postoperatively. This study aimed to investigate the factors contributing to SLN metastasis in underestimated IC patients with an initial diagnosis of DCIS by CNB. We retrospectively reviewed 1240 consecutive cases of DCIS by image-guided CNB from January 2010 to December 2017 and identified 316 underestimated IC cases with SLNB. Data on clinical characteristics, radiologic features, and final pathological findings were examined. Twenty-three patients (7.3%) had SLN metastasis. Multivariate analysis indicated that an IC tumor size > 0.5 cm (odds ratio: 3.11, p = 0.033) and the presence of lymphovascular invasion (odds ratio: 32.85, p < 0.0001) were independent risk predictors of SLN metastasis. In the absence of any predictors, the incidence of positive SLNs was very low (2.6%) in the total population and extremely low (1.3%) in the BCS subgroup. Therefore, omitting SLNB may be an acceptable option for patients who initially underwent BCS without risk predictors on final pathological assessment. Further prospective studies are necessary before clinical application.

Original languageEnglish
Article number4099
Issue number16
StatePublished - 02 08 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


  • Breast cancer
  • Ductal carcinoma in situ
  • Sentinel lymph node biopsy
  • Underestimation


Dive into the research topics of 'Predictors of sentinel lymph node metastasis in postoperatively upgraded invasive breast carcinoma patients'. Together they form a unique fingerprint.

Cite this